Trastuget Inj 440Mg 1'S Tp

Trastuget 440mg Injection by Getz Pharma contains Trastuzumab, a monoclonal antibody that treats HER2 positive breast cancer and metastatic gastric cancer. It is supplied as a lyophilized powder for intravenous infusion in a 30ml multi dose vial.

Trastuget 440mg Ingredients and Usage

Trastuget 440mg Injection contains Trastuzumab, a recombinant humanised IgG1 monoclonal antibody, as its active ingredient. Trastuzumab targets the HER2 (Human Epidermal Growth Factor Receptor 2) protein found at high levels on certain cancer cells. Oncologists prescribe Trastuget 440mg for cancers that test HER2 positive on diagnostic testing.

Trastuget 440mg treats HER2 positive early stage breast cancer as adjuvant therapy after surgery, often combined with anthracyclines, taxanes, or carboplatin. It also treats HER2 positive metastatic breast cancer, either alone or with paclitaxel as first line therapy.

The medicine is approved for HER2 positive metastatic gastric or gastroesophageal junction adenocarcinoma in combination with cisplatin and fluoropyrimidine chemotherapy. HER2 status must be confirmed by validated immunohistochemistry or in situ hybridisation testing before treatment.

How Does Trastuget 440mg Work?

Trastuget 440mg binds with high affinity to the extracellular domain IV of the HER2 receptor on cancer cell surfaces. This binding blocks the downstream signalling pathways that drive HER2 positive tumour cell growth and division. The drug also stops HER2 receptors from forming dimers with other HER family receptors that promote cancer progression.

Trastuzumab triggers antibody dependent cellular cytotoxicity (ADCC), where natural killer cells of the immune system recognise the antibody coated tumour cells and destroy them. The drug also causes internalisation and degradation of HER2 receptors, reducing receptor density on cancer cells.

The combined effect slows tumour growth, shrinks existing tumours, and improves survival outcomes in HER2 positive cancers. The medicine works best in patients whose tumours strongly overexpress HER2 protein.

Trastuget 440mg Side Effects

Trastuget 440mg can cause side effects that range from mild infusion reactions to serious organ toxicity. Patients receive monitoring during and after each infusion by the oncology team.

• Infusion related reactions including fever, chills, nausea, headache, and low blood pressure (most common with the first dose)

• Fatigue and weakness

• Nausea, vomiting, and diarrhoea

• Skin rash, itching, or hives

• Insomnia and headache

• Joint pain (arthralgia) and muscle pain (myalgia)

• Cough and shortness of breath

• Bone marrow suppression including neutropenia, anaemia, and leukopenia

• Raised liver enzyme levels

• Flu like symptoms

• Loss of appetite and weight loss

• Serious: cardiotoxicity, pulmonary toxicity, severe infusion reactions, and embryo fetal harm

Warnings

• Trastuget 440mg carries boxed warnings for cardiotoxicity, infusion reactions, pulmonary toxicity, and harm to the unborn baby.

• Trastuget can cause left ventricular dysfunction and congestive heart failure, especially when given with or after anthracycline chemotherapy such as doxorubicin.

• Patients require a baseline left ventricular ejection fraction (LVEF) assessment before treatment and repeat checks every 3 months during therapy.

• Stop Trastuget if LVEF drops significantly and seek cardiology review before considering resumption.

• Infusion reactions can occur during or within 24 hours of infusion and may include severe dyspnoea, bronchospasm, hypotension, or anaphylaxis.

• Do not give Trastuget as an intravenous push or bolus, and always infuse the loading dose over 90 minutes with the patient under observation.

• Trastuget can cause oligohydramnios and fetal harm, so women must use effective contraception during treatment and for 7 months after the final dose.

• Trastuget is contraindicated in patients with known hypersensitivity to murine proteins, trastuzumab, or any component of the formulation.

• Use caution in patients with severe dyspnoea at rest or those who need supplemental oxygen.

• Inform your oncologist about any history of heart disease, lung disease, or previous anthracycline exposure before starting Trastuget.

• The risk of cardiac and pulmonary toxicity rises when Trastuget is combined with paclitaxel or other chemotherapy agents.

• Trastuget is not recommended during breastfeeding due to the long half life of the antibody.

• Stop Trastuget immediately and seek emergency care for severe shortness of breath, chest pain, or signs of anaphylaxis.

Trastuget 440mg Storage Conditions

Store Trastuget 440mg lyophilized vials in a refrigerator between 2°C and 8°C in the original carton to protect from light. After reconstitution with the supplied bacteriostatic water for injection, the multi dose solution remains stable for 28 days when stored between 2°C and 8°C. Never freeze the reconstituted or diluted solution, and always keep Trastuget 440mg out of the reach and sight of children at the dispensing pharmacy or hospital storage facility.